Overview

The MSL Director, TTR is a medical-scientific expert that strategically supports the medical-scientific objectives of Alnylam’s TTR programs.

He/she will report to the Senior Medical Director, TTR Germany and will be leading the MSL team of the country. In this regard the MSL Director will ensure the implementation of the MSLs activity plan, which includes:

• Evidence generation
• Evidence dissemination and HCP education programs related to the science and clinical application of RNAi
• Key opinion leader engagement programs
• Operational excellence.

The MSL Director, TTR is expected to build effective cross-functional relationships with colleagues in Medical Affairs, Clinical Research, R&D, Patient Advocacy and Commercial, and other while maintaining full compliance with all relevant company, industry, legal, and regulatory requirements.

Key Responsibilities

• Lead, develop and coach a team of MSLs in the most efficient, effective and productive manner to reach set goals
• Develop and implement the MSL strategy and plan, including the support of launch readiness and post-launch medical as well as cross-functional programs and activities
• Ensure MSL collaboration with the Clinical Development team to ensure the timely and accurate implementation of research activities such a investigator initiated studies, collaborative studies and other clinical trials
• Identify key opinion leaders who are experts in ATTR polyneuropathy and cardiomyopathy and collaborate with them and their organizations/institutions in the context of medical-scientific programs
• Serve as a medical-scientific liaison for HCPs/the medical community and medical professional organizations and patient advocacy groups
• Provide medical-scientific input concerning the program of medical-scientific advisory board meetings and ensure optimal planning and accurate execution of advisory board meetings
• Collaborate with speakers to review (if required) their presentations in line with Alnylam’s SOPs and provide most accurate, objective and unbiased medical-scientific information if and when requested
• Provide educational medical-scientific meetings support at scientific congresses

Qualifications

• MD (Medical Doctor) and/or PhD and/or equivalent academically qualified professional. Degree in medical/natural science (PhD, MD) is preferred
• Profound experience as MSL in the life science industry (pharmaceutical and biotechnology companies) in the therapeutic areas of cardiology (preferred) neurology and rare diseases
• Highest degrees of work ethics
• Proven self, team and strategic leadership skills
• Ability to work in a matrix organization
• Proven solid basic science and/or clinical knowledge and expertize to enable peer-to-peer level conversations with HCPs
• Ability to cut through scientific complexity and synthesize complex content into clear and simple messages
• Experience in clinical research (including investigator-sponsored trials, collaborative studies and phase IV studies)
• Proven xperience in designing and implementing HCP education programs and KOL engagement programs
• Ability to work collaboratively and cross-functionally
• Excellent decision-making skills and ability to fully assume responsibility and accountability
• Scientific publication experience is a plus
• Dedicated, energetic and passionate about making a meaningful difference for patients and their caregivers
• Outstanding interpersonal skills, including building strong working relationships, and managing and resolving conflict
• Excellent communication skills, including presentation skills
• An unwavering commitment to upholding the highest ethical, legal, regulatory and scientific standards
• Fluent in German and English, both written and verbal
• Willing to travel 60% of the time

About Alnylam: Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.